Drug Profile
Research programme: small molecules antiviral therapeutics - ABIVAX/ Evotec SE
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Abivax; Evotec AG
- Developer Abivax; Evotec SE
- Class Antivirals; Small molecules
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
- No development reported Dengue; Influenza virus infections
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Dengue in France
- 28 Oct 2021 No recent reports of development identified for research development in Dengue in Germany
- 28 Oct 2021 No recent reports of development identified for research development in Influenza-virus-infections in France